Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/56134 |
Resumo: | These authors contributed equally: Derek A. T. Cummings, Natalie E Dean, Jason R. Andrews, Albert I. Ko, Julio Croda. |
| id |
CRUZ_5e06355044ea3e4dd177047e55dd7440 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/56134 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Ranzani, Otavio T.Hitchings, Matt D. T.Melo, Rosana Leite deFrança, Giovanny V. A. deFernandes, Cássia de Fátima R.Lind, Margaret L.Torres, Mario Sergio ScaramuzziniTsuha, Daniel HenriqueDavid, Leticia C. S.Said, Rodrigo F. C.Almiron, MariaOliveira, Roberto D. deCummings, Derek A. T.Dean, Natalie E.Andrews, Jason R.Ko, Albert I.Croda, Julio2022-12-21T17:12:03Z2022-12-21T17:12:03Z2022RANZANI, Otavio T. et al. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against the Omicron in Brazil. Nature Communications, p. 1-10, 2022.https://www.arca.fiocruz.br/handle/icict/5613410.1038/s41467-022-33169-0These authors contributed equally: Derek A. T. Cummings, Natalie E Dean, Jason R. Andrews, Albert I. Ko, Julio Croda.We thank the Pan American Health Organization for its support. No external funding was provided for this study. OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 programme (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA) programme. DATC and MDH report a contract from Merck (to the University of Florida) for research unrelated to this manuscript. These institutions had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.Universitat Pompeu Fabra. Barcelona Institute for Global Health. ISGlobal. Barcelona, Spain / Faculdade de Medicina. Hospital das Clínicas. Heart Institute. Pulmonary Division. São Paulo, SP, Brazil / CIBER Epidemiología y Salud Pública (CIBERESP). Madrid, Spain.University of Florida. College of Public Health & Health Professions. Department of Biostatistics. Gainesville, FL, USA.Ministério da Saúde. Secretaria Extraordinária de Enfrentamento à Covid-19. Brasília, DF, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brazil.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.Secretary of Manaus. Municipal Health. Manaus, AM, Brazil.Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brazil.Pan American Health Organization, Brasilia, DF, Brazil.Pan American Health Organization, Brasilia, DF, Brazil.Pan American Health Organization, Brasilia, DF, Brazil.State University of Mato Grosso do Sul, Dourados, MS, Brazil.University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute, Gainesville, FL, USA.Emory University. Rollins School of Public Health. Department of Biostatistics & Bioinformatics, Atlanta, GA, USA.Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, USA.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brazil / Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil.The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, testnegative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.engNatureCOVID-19VacinasCoronaVacVacina BNT162Estudos de Casos e ControlesImunização SecundáriaCOVID-19VaccinesCoronaVacBNT162b2Case-control studyBoosterCOVID-19VacinasCoronaVacVacina BNT162Estudos de Casos e ControlesImunização SecundáriaEffectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALRanzani_Otavio_etal_FIOCRUZ_MS_2022_COVID-19.pdfRanzani_Otavio_etal_FIOCRUZ_MS_2022_COVID-19.pdfapplication/pdf833989https://www.arca.fiocruz.br/bitstream/icict/56134/3/Ranzani_Otavio_etal_FIOCRUZ_MS_2022_COVID-19.pdf1ef70112f981f442fc42e6e80ff16012MD53LICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/56134/1/license.txt5a560609d32a3863062d77ff32785d58MD51icict/561342022-12-21 14:44:08.121oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-12-21T17:44:08Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.en_US.fl_str_mv |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| spellingShingle |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil Ranzani, Otavio T. COVID-19 Vacinas CoronaVac Vacina BNT162 Estudos de Casos e Controles Imunização Secundária COVID-19 Vaccines CoronaVac BNT162b2 Case-control study Booster COVID-19 Vacinas CoronaVac Vacina BNT162 Estudos de Casos e Controles Imunização Secundária |
| title_short |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_full |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_fullStr |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_full_unstemmed |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| title_sort |
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil |
| author |
Ranzani, Otavio T. |
| author_facet |
Ranzani, Otavio T. Hitchings, Matt D. T. Melo, Rosana Leite de França, Giovanny V. A. de Fernandes, Cássia de Fátima R. Lind, Margaret L. Torres, Mario Sergio Scaramuzzini Tsuha, Daniel Henrique David, Leticia C. S. Said, Rodrigo F. C. Almiron, Maria Oliveira, Roberto D. de Cummings, Derek A. T. Dean, Natalie E. Andrews, Jason R. Ko, Albert I. Croda, Julio |
| author_role |
author |
| author2 |
Hitchings, Matt D. T. Melo, Rosana Leite de França, Giovanny V. A. de Fernandes, Cássia de Fátima R. Lind, Margaret L. Torres, Mario Sergio Scaramuzzini Tsuha, Daniel Henrique David, Leticia C. S. Said, Rodrigo F. C. Almiron, Maria Oliveira, Roberto D. de Cummings, Derek A. T. Dean, Natalie E. Andrews, Jason R. Ko, Albert I. Croda, Julio |
| author2_role |
author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Ranzani, Otavio T. Hitchings, Matt D. T. Melo, Rosana Leite de França, Giovanny V. A. de Fernandes, Cássia de Fátima R. Lind, Margaret L. Torres, Mario Sergio Scaramuzzini Tsuha, Daniel Henrique David, Leticia C. S. Said, Rodrigo F. C. Almiron, Maria Oliveira, Roberto D. de Cummings, Derek A. T. Dean, Natalie E. Andrews, Jason R. Ko, Albert I. Croda, Julio |
| dc.subject.other.en_US.fl_str_mv |
COVID-19 Vacinas CoronaVac Vacina BNT162 Estudos de Casos e Controles Imunização Secundária |
| topic |
COVID-19 Vacinas CoronaVac Vacina BNT162 Estudos de Casos e Controles Imunização Secundária COVID-19 Vaccines CoronaVac BNT162b2 Case-control study Booster COVID-19 Vacinas CoronaVac Vacina BNT162 Estudos de Casos e Controles Imunização Secundária |
| dc.subject.en.en_US.fl_str_mv |
COVID-19 Vaccines CoronaVac BNT162b2 Case-control study Booster |
| dc.subject.decs.en_US.fl_str_mv |
COVID-19 Vacinas CoronaVac Vacina BNT162 Estudos de Casos e Controles Imunização Secundária |
| description |
These authors contributed equally: Derek A. T. Cummings, Natalie E Dean, Jason R. Andrews, Albert I. Ko, Julio Croda. |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-12-21T17:12:03Z |
| dc.date.available.fl_str_mv |
2022-12-21T17:12:03Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
RANZANI, Otavio T. et al. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against the Omicron in Brazil. Nature Communications, p. 1-10, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/56134 |
| dc.identifier.doi.none.fl_str_mv |
10.1038/s41467-022-33169-0 |
| identifier_str_mv |
RANZANI, Otavio T. et al. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against the Omicron in Brazil. Nature Communications, p. 1-10, 2022. 10.1038/s41467-022-33169-0 |
| url |
https://www.arca.fiocruz.br/handle/icict/56134 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Nature |
| publisher.none.fl_str_mv |
Nature |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/56134/3/Ranzani_Otavio_etal_FIOCRUZ_MS_2022_COVID-19.pdf https://www.arca.fiocruz.br/bitstream/icict/56134/1/license.txt |
| bitstream.checksum.fl_str_mv |
1ef70112f981f442fc42e6e80ff16012 5a560609d32a3863062d77ff32785d58 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009105096278016 |